Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Dados básicos
- Código:
- Ensaio Clínico Académico (INITIATE-HFrEF)
- Protocolo:
- Ensaio Clínico Académico (INITIATE-HFrEF)
- EUDRACT:
- 2022-502409-14-00
- NCT:
- NCT05989503
- Centro:
- Dotação:
- Ano de início:
- 2023
- Ano de conclusão:
Objectivos do projeto
Ensaio Clínico – Iniciativa do Investigador; Fase: IV – Aleatorizado; Subtipo: Tratamento – Medicamento (de baixo nivel de intervenção); Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Multicêntrico – 4 Centros de Cuidados Secundários – Centros de Ensaio: CHUSJ/CHVNGE/CHUdSA/Hospital Pedro Hispano; Doença investigada: Insuficiência cardíaca – Participantes recrutados: 20
Documentos
- Não há documentos
Participantes
-
Francisco Aguiar Vasques Novoa Faria
Sub-Investigador
-
Joana Lídia Martins Pimenta
Sub-Investigador
-
Francisca Almeida Saraiva
Investigador Colaborador
-
João Pedro Melo Marques Pinho Ferreira
Investigador Principal
-
Ana Marta Matos Silva
Investigador Colaborador
-
Mário André Da Silva Santos
Sub-Investigador
-
Cristina Maria Rodrigues Pinheiro Gavina
Sub-Investigador
Unidades de investigação
-
RISE-Health
Investigador
Fernando Carlos De Landér Schmitt
Stakeholders - Promotores
Outputs do ensaio clínico
LoRaWAN Based Street Lighting for Remote Areas with Shadow Zones
Ferreira, Joao; (...); Agreira, C. I. Faustino
Proceedings Paper. 10.1109/MELECON56669.2024.10608473. 2024
A 4-variable model to predict cardio-kidney events and mortality in chronic kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) Study
Mendon?a, L.; (...); Ferreira, J.
Article. 10.1159/000533223. 2023
Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction.
Moreira-Costa, L; (...); Lourenço, AP
Article. 2024
Acute heart failure - an EFIM guideline critical appraisal and adaptation for internists
Kokorin, Valentin A.; (...); Lesniak, Wiktoria
Article. 10.1016/j.ejim.2024.02.028. 2024
Acute heart failure - an EFIM guideline critical appraisal and adaptation for internists.
Kokorin, VA; (...); Lesniak, W
Article. 2024
Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure
Kobayashi M.; (...); Ferreira J.P.
Article. 10.1016/j.ijcard.2024.132477. 2024
AGE-STRATIFIED CARDIOVASCULAR RISK PROFILING USING SCORE2 AND SCORE2-OP MODELS
Gavina, Cristina; (...); Araujo, Francisco
Meeting Abstract. 2024
An Analysis From a Tertiary Pediatric Hospital: Does Physical Activity Play a Role in the Management of Children and Young Adults With Osteogenesis Imperfecta?
Saraiva, Francisca Galhardo; (...); Campagnolo, Joao Lameiras
Article. 10.7759/cureus.53646. 2024
Aortic stenosis rapid progression is associated with premature cardiac damage independently of baseline severity
Teixeira, R; (...); Fontes-Carvalho, R
Meeting Abstract. 2023
Author Correction: The European Reference Genome Atlas: piloting a decentralised approach to equitable biodiversity genomics.
Mc Cartney AM; (...); Mazzoni CJ
Correction. 10.1038/s44185-024-00065-3. 2024
Authors reply in response to a letter on "Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study"
Roncon Albuquerque, R.; (...); Paiva, JA
Letter. 10.1186/s13613-023-01215-9. 2023
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
Packer, M; (...); Anker, SD
Article. 10.1161/CIRCULATIONAHA.123.065748. 2023
Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial
Sattar N.; (...); Anker S.D.
Article. 10.1002/ejhf.3221. 2024
Body mass index effect on long-term survival after coronary artery bypass surgery: a competing risk analysis
Abreu, A; (...); Leite-Moreira, A
Article. 10.1093/icvts/ivad161. 2023
Can Breastfeeding Prevent Long-Term Overweight and Obesity in Children? A Population-Based Cohort Study
Roldao, Carolina; (...); Taveira-Gomes, Tiago
Article. 10.3390/nu16162728. 2024
Can Breastfeeding Prevent Long-Term Overweight and Obesity in Children? A Population-Based Cohort Study.
Roldao, C; (...); Taveira-Gomes, T
Article. 2024
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme
Ferreira, JP; (...); Januzzi, JL
Article. 10.1002/ejhf.3166. 2024
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Colombo G.; (...); Inciardi R.M.
Review. 10.1002/ehf2.15095. 2024
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
Neves J.S.; (...); Ferreira J.P.
Article. 10.1002/ejhf.3478. 2024
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
Razaghizad, A; (...); Sharma, A
Article. 10.1111/dom.15768. 2024
Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed
Ferreir, Joao Pedro, Neves, Joao Sergio, Saraiva, Francisca
Editorial Material. 10.1016/j.cardfail.2023.12.002. 2024
Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed.
Ferreira, JP, Neves, JS, Saraiva, F
Article. 2024
Cardiovascular remodelling and reverse remodelling during pregnancy and postpartum: Looking at the right side
Ferreira A.F.; (...); Falcão-Pires I.
Article. 10.1016/j.preghy.2024.101171. 2024
Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling (vol 325, pg H774, 2023)
Ferreira, Ana Filipa; (...); Falcao-Pires, Ines
Correction. 10.1152/ajpheart.00200.2023_COR. 2024
Cardiovascular risk profile with SCORE2 and SCORE2-OP: comparing Portugal, Spain, Italy, and France using the new European predictive models
Fontainhas, Mariana; (...); Araujo, Francisco
Article. 10.3389/fcvm.2024.1509240. 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF
Shen L.; (...); McMurray J.J.V.
Article. 10.1161/CIRCULATIONAHA.124.070553. 2024
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study
Ferreira J.P.; (...); Leite-Moreira A.
Article. 10.1016/j.atherosclerosis.2024.117461. 2024
Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study.
Ferreira, JP; (...); Leite-Moreira, A
Article. 2024
Corrigendum: Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis(Front. Cardiovasc. Med., (2024), 11, (1407566), 10.3389/fcvm.2024.1407566)
Sousa Nunes F.; (...); Sousa C.
Correction. 10.3389/fcvm.2024.1471225. 2024
Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study
Gavina, C; (...); Taveira-Gomes, T
Article. 10.1002/clc.24183. 2023
Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.
Gavina, C; (...); Taveira Gomes, T
Article. 2024
DISSECTING SEXUAL DIMORPHISM IN AORTIC VALVE STENOSIS BY PROTEOMICS
Grego, Ana; (...); Trindade, Fabio
Meeting Abstract. 2024
Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
Ferreira J.P., MENDONÇA L.U.Í.S., NEVES J.S.
Article. 10.1016/j.cardfail.2024.05.006. 2024
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved
Rastogi, T; (...); Zannad, F
Article. 10.1002/ejhf.3136. 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Dewan P.; (...); McMurray J.J.V.
Article. 10.1161/CIRCULATIONAHA.124.068774. 2024
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.3101. 2023
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
Wei, FF; (...); Staessen, JA
Article. 10.1038/s41440-024-01843-z. 2024
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF
Dhingra, NK; (...); Packer, M
Article. 10.1016/j.jchf.2023.06.036. 2024
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF.
Dhingra, NK; (...); Packer, M
Article. 2024
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved
Coats, AJS; (...); Anker, SD
Article. 10.1002/jcsm.13393. 2024
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis
Ferreira, JP; (...); Anker, S
Article. 10.1002/ejhf.3180. 2024
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes
Ribeiro, Eduarda; (...); Vale, Nuno
Article. 10.3390/jcm13144113. 2024
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes.
Ribeiro, E; (...); Vale, N
Article. 2024
Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort
Vasques-Nóvoa F.; (...); Friões F.
Article. 10.1007/s00392-024-02535-x. 2024
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program
Ferreira, JP; (...); Zannad, F
Article. 10.1002/ejhf.3078. 2024
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program.
Ferreira, JP; (...); Zannad, F
Article. 2024
Heart Failure in Brazil and the Need to Measure and Take Action
Rivas-Lasarte, M, Ferreira, JP
Editorial Material. 10.1016/j.cardfail.2023.10.485. 2024
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure
Wei F.-F.; (...); Staessen J.A.
Article. 10.1002/ehf2.15000. 2024
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial
Monzo, L; (...); Zannad, F
Article. 10.1016/j.cardfail.2023.11.020. 2024
High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
Monzo, L; (...); Zannad, F
Article. 2024
High-Caloric Diets in Adolescence Impair Specific GABAergic Subpopulations, Neurogenesis, and Alter Astrocyte Morphology.
Mota, B; (...); Cardoso, A
Article. 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
Ferreira, JP; (...); Solomon, SD
Article. 10.1016/j.ijcard.2024.131818. 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.
Ferreira, JP; (...); Solomon, SD
Article. 2024
Home- versus centre-based EXercise InTervention in patients with Heart Failure (EXIT-HF trial): A pragmatic randomized controlled trial
Schmidt, C; (...); Santos, M
Article. 10.1016/j.repc.2023.05.013. 2024
Home- versus clinic-based exercise intervention in patients with heart failure (EXIT-HF trial): a pragmatic randomized controlled trial
Santos, M; (...); Ribeiro, F
Meeting Abstract. 2023
Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients
Brandao, M; (...); Ferreira, JP
Article. 10.55563/clinexprheumatol/ua087b. 2023
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis
Talha, KM; (...); Packer, M
Article. 10.1111/dom.15572. 2024
Influence of iron deficiency definition on the efficacy of intravenous iron in heart failure: a meta-analysis of randomized trials
Marques P.; (...); Ferreira J.P.
Article. 10.1007/s00392-024-02557-5. 2024
Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury
Garcia, Bruno; (...); Herpain, Antoine
Article. 10.1186/s40635-024-00638-3. 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme
Ferreira J.P.; (...); Januzzi J.L.
Article. 10.1002/ejhf.3227. 2024
Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?
Marques P., Sharma A., Ferreira J.P.
Editorial Material. 10.1016/j.jchf.2024.01.011. 2024
Long-term cardiovascular outcomes in a population-based multicentric cohort of northern Portugal: Validation of the ESC/EAS prognostic risk classification
Gavina, Cristina; (...); Araujo, Francisco
Article. 10.1016/j.jacl.2024.04.002. 2024
Long-term cardiovascular outcomes in a population-based multicentric cohort of northern Portugal: Validation of the ESC/EAS prognostic risk classification.
Gavina, C; (...); Araújo, F
Article. 2024
Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial.
Cruz, M; (...); Pimenta, J
Article. 2024
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad F.; (...); Harrison S.A.
Review. 10.1111/joim.13793. 2024
Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials
Ferreira J.P.; (...); Neves J.S.
Article. 10.1159/000541686. 2024
Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients
Ferreira, JP, Rossello, X, Zannad, F
Editorial Material. 10.1002/ejhf.3098. 2023
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Ferreira, JP, Pitt, B, Zannad, F
Review. 10.1161/CIRCHEARTFAILURE.124.011629. 2024
Missed opportunities in the diagnosis of heart failure: a real-world assessment
Ferreira, JP; (...); Gavina, C
Article. 10.1002/ehf2.14531. 2023
National registries for rare clinical conditions: Networking to promote evidence-based healthcare
Leite-Moreira, AF, Saraiva, F
Editorial Material. 10.1016/j.repc.2023.03.007. 2023
Office- versus home-based evaluation of quality of life in heart failure with reduced ejection fraction: A randomized study
de Almeida Pinho I.; (...); Ferreira J.P.
Article. 10.1016/j.ijcard.2024.132341. 2024
Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial
Razaghizad, A; (...); Sharma, A
Article. 10.1016/j.cardfail.2023.10.474. 2024
Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial.
Razaghizad, A; (...); Sharma, A
Article. 2024
Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia
Ferreira J.P.
Editorial Material. 10.1016/j.jchf.2024.07.020. 2024
Perceptions of cardiology, professional preferences and impact on career choices among Portuguese cardiologists: Results from the Portuguese Society of Cardiology's Women and Cardiology Task Force survey
Timoteo, Ana Teresa; (...); Goncalves, Lino
Article. 10.1016/j.repc.2023.07.004. 2024
Perceptions of cardiology, professional preferences and impact on career choices among Portuguese cardiologists: Results from the Portuguese Society of Cardiology's Women and Cardiology Task Force survey.
Timóteo, AT; (...); Gonçalves, L
Article. 2024
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.
Santos Ferreira, D; (...); Zannad, F
Article. 2024
Polypill use for the prevention of cardiovascular disease: A position paper
Araujo, Francisco; (...); Gavina, Cristina
Review. 10.1016/j.repc.2023.02.011. 2023
Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design - A population-based study
Baptista, R; (...); Gavina, C.
Article. 10.1016/j.repc.2023.10.004. 2023
Potential for organ donation after controlled circulatory death: a retrospective analysis
Dias, FS; (...); Paiva, J.
Article. 10.1097/j.pbj.0000000000000259. 2024
Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?
Ramos, P; (...); Pacheco-Figueiredo, L
Article. 10.1016/j.urolonc.2024.01.009. 2024
Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention
Santos-Ferreira, D; (...); Fontes-Carvalho, R
Article. 10.1007/s10554-023-02992-x. 2023
Prognostic value of flow-status in severe aortic stenosis patients undergoing percutaneous intervention.
Santos Ferreira, D; (...); Fontes Carvalho, R
Article. 2024
Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort
Kobayashi M.; (...); Girerd N.
Article. 10.1002/ejhf.3202. 2024
Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there
Zannad F., Ferreira J.P.
Editorial Material. 10.1093/eurheartj/ehae399. 2024
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program
Packer M.; (...); Zannad F.
Article. 10.1016/j.jacc.2024.07.013. 2024
REGIONAL AND COUNTRY-SPECIFIC VARIATIONS IN CARDIOVASCULAR RISK PROFILES: A REAL-WORLD ANALYSIS
Araujo, Francisco; (...); Gavina, Cristina
Meeting Abstract. 2024
Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'
Ferreira, JP, Voors, AA
Editorial Material. 10.1002/ejhf.3415. 2024
Reply to the letter entitled “Inflammation in Heart Failure with Preserved Ejection Fraction: A Bystander or A Participant?” by Zhong M and Yan X
Ferreira J.P., Zannad F., Solomon S.D.
Letter. 10.1016/j.ijcard.2024.132278. 2024
Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis
Sousa Nunes F.; (...); Sousa C.
Review. 10.3389/fcvm.2024.1407566. 2024
Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France
Baudry, G; (...); Girerd, N
Article. 10.1002/ejhf.3103. 2023
Semaglutide and Cardiovascular Outcomes
Neves, JS, Leite, AR, Ferreira, JP
Letter. 10.1056/NEJMc2400414. 2024
Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study
Gavina, C; (...); Taveria-Gomes, T
Article. 10.1016/j.atherosclerosis.2023.05.017. 2023
Sex-based differences and risk of recurrence in patients with atrial fibrillation undergoing pulmonary vein isolation
Aguiar-Neves, Ines; (...); Fontes-Carvalho, Ricardo
Article. 10.1016/j.ijcard.2024.132161. 2024
Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?
Neves J.S.; (...); Ferreira J.P.
Article. 10.1016/j.jacc.2024.06.026. 2024
Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study
Roncon Albuquerque, R.; (...); Paiva, J.
Article. 10.1186/s13613-023-01185-y. 2023
Stretch-induced compliance mechanism in pregnancy-induced cardiac hypertrophy and the impact of cardiovascular risk factors
Ferreira A.F.; (...); Falcão-Pires I.
Article. 10.1152/ajpheart.00701.2023. 2024
Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort
Alexandre A.; (...); Rodrigues P.
Article. 10.1007/s00392-024-02548-6. 2024
TARGETING PREMATURE AGING TO IMPROVE HFPEF
Silva, E. D.; (...); Nascimento, D. S.
Meeting Abstract. 2023
The European Reference Genome Atlas: piloting a decentralised approach to equitable biodiversity genomics.
Mc Cartney AM; (...); Mazzoni CJ
Article. 10.1038/s44185-024-00054-6. 2024
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes A Meta-Analysis of Randomized Placebo-Controlled Trials
Mendonça, L; (...); Ferreira, JP
Article. 10.2215/CJN.0000000584. 2024
The win ratio in cardiology trials: lessons learnt, new developments, and wise future use
Pocock, SJ; (...); Stone, GW
Review. 10.1093/eurheartj/ehae647. 2024
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE
Ferreira, JP; (...); Voors, AA
Article. 10.1002/ejhf.3369. 2024
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial
Tromp J.; (...); Voors A.A.
Article. 10.1002/ejhf.3218. 2024
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Doehner W.; (...); Packer M.
Article. 10.1016/j.jchf.2024.08.020. 2024
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Yu, YL; (...); Staessen, JA
Article. 10.1136/heartjnl-2023-323796. 2024
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
Khan, MS; (...); Butler, J
Article. 10.1016/j.cardfail.2023.06.024. 2023
Freedom And Smart Solo Stentless Bioprosthesis For Aortic Valve Replacement - Clinical And Hemodynamic Evaluation-Systematic Review And Meta-Analysis
Projeto de fim de curso
Colaboradores: Francisca Almeida Saraiva